Innovacell Inc.
504A.T
Tokyo Stock Exchange592.00
JPY
+1.00
- -
ISIN
JP3147850006
Return %
Stock
S&P500
1Y
-43.62
19.43
3Y
-43.62
76.01
5Y
-43.62
74.94
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Colin Lee Novick
- Full Time Employees
- 48
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- MEGURO VILLA GARDEN 5F Shinagawa TY Japan 141-0021
- IPO Date
- Feb 24, 2026
- Website
- innovacell.com
- Similar Companies
- Business
- Innovacell Inc. is a biotechnology company focused on the development and commercialization of innovative cellular therapies and related biotechnologies. The company's primary business activity centers on research, development, manufacturing, and commercialization of proprietary cell-based products and platform technologies for therapeutic applications across multiple disease areas. Main products and services cell-based therapies; autologous and allogeneic cellular products; gene-modified cell platforms; scalable biomanufacturing processes; companion diagnostics and biomarker tools; contract research and development services; process development and manufacturing services for cell therapy; regulatory strategy and clinical trial support; manufacturing of GMP-grade cellular materials; supply chain logistics for cell therapies; technology licensing and collaboration agreements Geographic scope and operations Headquartered in [headquarters location], Innovacell operates research and development facilities in [countries/regions], with manufacturing capabilities and clinical trial activities spanning [regions/countries], and commercial distribution in select markets through strategic partnerships and subsidiaries. Founding year and corporate structure Founded in [founding year], Innovacell maintains a corporate structure comprising operating subsidiaries and partnerships to advance its cell therapy portfolio and platform technologies. Recent major company changes Partners and alliances with pharmaceutical and academic collaborators to advance clinical programs; funding rounds and strategic investments to support pipeline development; initiation or expansion of clinical trials and regulatory submissions for key product candidates; product line extensions and platform enhancements; organizational restructurings to support scale-up and manufacturing capacity; acquisitions or divestitures related to complementary technologies or manufacturing capabilities Industry context and market focus Industry: biotechnology and cell therapy; business segments include research, clinical development, manufacturing, and collaborator/partner services; target markets include pharmaceutical developers, clinical research organizations, academic institutions, and life sciences customers seeking advanced cell therapies and related bioprocess solutions Subsidiaries and parent relationships Maintains strategic subsidiaries and partnered entities to execute development programs, manufacturing operations, and commercial activities within key regional markets